Cerebrospinal fluid diversion for leptomeningeal metastasis: palliative, procedural and oncologic outcomes

• Published in: Journal of neuro-oncology 2021-09, Vol.154 (3), p.301-313
• Main Authors: Bander, Evan D., Yuan, Melissa, Reiner, Anne S., Garton, Andrew L. A., Panageas, Katherine S., Brennan, Cameron W., Tabar, Viviane, Moss, Nelson S.
• Format: Article
• Language: English
• Subjects: Brain cancer; Brain Neoplasms; Cerebrospinal fluid; Clinical Study; Decision making; Diagnosis; Hematoma; Humans; Hydrocephalus; Hypertension; Intracranial Hypertension; Malignancy; Medical prognosis; Medicine; Medicine & Public Health; Meningeal Carcinomatosis - therapy; Meninges; Metastases; Metastasis; Neurology; Oncology; Palliation; Patients; Peritoneal seeding; Population studies; Prognosis; Rehabilitation; Retrospective Studies; Risk factors; Survival; Tumors
• ISSN: 0167-594X; 1573-7373
• DOI: 10.1007/s11060-021-03827-2

Background Leptomeningeal metastasis (LM) occurs in 3–5% of patients with solid metastatic tumors and often portends a severe prognosis including symptomatic hydrocephalus and intracranial hypertension. Cerebrospinal fluid (CSF) shunting can provide symptomatic relief in this patient subset; however, few studies have examined the role of shunting in the palliation, prognosis and overall oncologic care of these patients. Objective To identify and evaluate risk factors associated with prognosis after CSF diversion and assess surgical, symptomatic and oncologic outcomes in this population. Methods A retrospective study was conducted on patients with solid-malignancy LM treated with a shunt at a NCI-designated Comprehensive Cancer Center between 2010 and 2019. Results One hundred and ninety patients with metastatic LM underwent CSF diversion. Overall survival was 4.14 months from LM diagnosis (95% CI: 3.29–4.70) and 2.43 months (95% CI: 2.01–3.09) from shunting. Karnofsky performance status (KPS) at time of shunting and brain metastases (BrM) number at LM diagnosis demonstrated significant associations with survival (HR = 0.66; 95% CI [0.51–0.86], p = 0.002; HR = 1.40; 95% CI [1.01–1.93] per 10 BrM, p = 0.04, respectively). Eighty-three percent of patients experienced symptomatic relief, and 79% were discharged home or to rehabilitation facilities post-shunting. Post-shunt, 56% of patients received additional systemic therapy or started or completed WBRT. Complications included infection (5%), symptomatic subdural hygroma/hematoma (6.3%), and shunt externalization/removal/repair (8%). Abdominal seeding was not identified. Conclusions CSF diversion for LM with hydrocephalus and intracranial hypertension secondary to metastasis can achieve symptomatic relief, hospital discharge, and return to further oncologic therapy, with a complication profile unique to this pathophysiology. However, decision-making in this population must incorporate end-of-life goals of care given limited prognosis.